The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

Sponsor
Bo Feldt-Rasmussen
Study ID
NCT02284230
Phase
PHASE2
Status
Withdrawn

Conditions

  • Kidney Failure, Chronic
  • Prediabetic State

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD). The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives include various clinical and biochemical cardiovascular and safety parameters. We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate other cardiovascular risk factors.

Key Dates

Start date
Dec 31, 2014
Status verified
Aug 2015
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide treatment
    Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
  • Placebo Comparator: Placebo treatment
    Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.

Primary Outcome Measure

Plasma glucose during oral glucose tolerance test at week 26 [ Time Frame: The trial visit of week 26 ]

Related Studies